Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Stock news
There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Biomerica ( NASDAQ:BMRA...
* Biomerica expects completion of enrollment of its Irritable Bowel Syndrome Diagnostic-Guided Therapy clinical trial by end of April, 2021 * FDA actively reviewing Company’s EUA submission for its first of its kind “at-home” Blood Collection kit used with the Biomerica COVID-19 IgG ELISA Lab Test system * Simple to use 15-minute COVID-19 Antigen Rapid Test, which now has CE Mark, receives first large ordersIRVINE, Calif., Jan. 15, 2021 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMR...
Companies in the news are: ACI, GM, BMRA, LMNL
* Biomerica receives first orders and plans to ship tests in coming weeks * Clinical studies demonstrated an overall performance of 94.7% positive agreement (sensitivity) and 99.7% negative agreement (specificity) as compared to lab-based molecular PCR testsIRVINE, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today announced it has received CE Mark for its new COVID-19 Rapid Antigen Test for detection of COVID-19 ...
Some Biomerica, Inc. ( NASDAQ:BMRA ) shareholders are probably rather concerned to see the share price fall 32% over...
By M. Marin NASDAQ:BMRA READ THE FULL BMRA RESEARCH REPORT Last week, Biomerica (NASDAQ:BMRA) announced that it is nearing completion of patient enrollment in the InFoods® IBS endpoint clinical trial. As a diagnostic-guided therapy (not a drug), InFoods does not have the side effects drugs often have and can be used alone and/or as part of a drug therapy program. Patient enrollments are expected
* Patient enrollment completion anticipated by the end of April 2021 * InFoods® Diagnostic-Guided Therapy is designed to address the $30 billion market for IBS treatment * Therapy seeks to identify patient-specific foods that trigger IBS symptoms and suffering * Approximately 45 million Americans suffer from IBS1IRVINE, Calif., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today announced it is nearing completion of patient...